S&P Futures
3,851.25 +3.00 (+0.08%) Dow Futures
31,042.00 +29.00 (+0.09%) Nasdaq Futures
11,896.00 +15.75 (+0.13%) Russell 2000 Futures
1,732.00 +3.40 (+0.20%) Crude Oil
99.18 +0.65 (+0.66%) Gold
1,744.30 +7.80 (+0.45%)
Adaptimmune Therapeutics plc (ADAP)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.6600 |
| Open | 1.6500 |
| Bid | 1.7000 x 1100 |
| Ask | 1.8300 x 900 |
| Day's Range | 1.6500 - 1.8000 |
| 52 Week Range | 1.2600 - 6.8600 |
| Volume | |
| Avg. Volume | 578,076 |
| Market Cap | 280.293M |
| Beta (5Y Monthly) | 2.07 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0920 |
| Earnings Date | May 09, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.67 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ADAP
Related Research
- Adaptimmune Therapeutics plcAnalyst Report: BioNTech SEBioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product.RatingFair ValueEconomic Moat8 days agoMorningstar
- Motley Fool
Got $500? 3 Absurdly Cheap Healthcare Stocks That Are Set to Skyrocket
Here's why these Fool.com contributors are bullish on Adaptimmune Therapeutics, G1 Therapeutics, and Axsome Therapeutics.
- Simply Wall St.
What Kind Of Investors Own Most Of Adaptimmune Therapeutics plc (NASDAQ:ADAP)?
If you want to know who really controls Adaptimmune Therapeutics plc ( NASDAQ:ADAP ), then you'll have to look at the...
- Motley Fool
Why Adaptimmune Therapeutics Stock Is Popping Today
Shares of the British cell therapy company Adaptimmune Therapeutics (NASDAQ: ADAP) are having one of their best days in several months today. To put this move into the proper context, the bellwether biotech indices -- the iShares Biotechnology ETF and the SPDR S&P Biotech ETF -- are both essentially flat for the day at the time of this writing. Adaptimmune's shares appear to be perking up in response to the buyout of fellow soft tissue cancer specialist Epizyme (NASDAQ: EPZM) earlier today.
